TL;DR
Researchers have developed a potent human antibody, JMB2002, that effectively neutralizes multiple SARS-CoV-2 variants, including the concerning B.1.351 strain. This antibody demonstrated significant prophylactic and therapeutic efficacy in rhesus macaques, offering a promising new avenue for combating the COVID-19 pandemic.
What Problem Does This Paper Address?
The emergence of SARS-CoV-2 variants, such as B.1.351, poses a significant challenge to existing therapeutic strategies, as these variants often exhibit increased resistance to neutralization by antibodies found in convalescent plasma or generated by vaccines. The need for broadly neutralizing antibodies that can effectively combat these evolving strains is critical for controlling the ongoing COVID-19 pandemic. This paper addresses the challenge of rapidly identifying and developing such antibodies.
Methods
The study employed a novel phage-to-yeast (PtY) display platform for the rapid identification of potent neutralizing antibodies (nAbs). This platform combines the advantages of phage display and yeast display, allowing for efficient screening of large antibody libraries. Key steps included:
- Library construction: Naïve human B cell scFv libraries were constructed from PBMCs, spleens, and bone marrow of healthy human subjects.
- Phage display selection: Two rounds of phage selection were performed to enrich for binders to biotinylated SARS-CoV-2 RBD.
- Yeast display transformation: Enriched scFv DNA was transferred into yeast for display.
- Competitive FACS sorting: A novel competitive fluorescence-activated cell sorting (FACS) approach was developed to identify potential blocking antibodies. This involved incubating the yeast library with SARS-CoV-2 RBD and biotinylated hACE2, then labeling with fluorescent antibodies to identify clones that could block RBD-hACE2 binding.
- Antibody production and characterization: Lead candidates were expressed as monospecific IgG antibodies in mammalian cells. Their affinity, blocking activity, epitope binding, neutralization capabilities (in vitro and in vivo), and biophysical properties were thoroughly evaluated.
- Fc modification for ADE reduction: To mitigate the risk of antibody-dependent enhancement (ADE), an N297A mutation was introduced into the Fc region of the lead antibody, resulting in JMB2002.
Datasets
The study utilized antibody libraries derived from healthy human subjects. The SARS-CoV-2 virus (strain WIV04) and its various RBD and S1 protein variants were used for binding and neutralization assays. No new benchmark datasets were introduced.
Key Insights and Ideas
- PtY Display Platform Efficiency: The PtY platform proved remarkably efficient, enabling the identification of potent nAbs within just 10 days, significantly accelerating the discovery process compared to traditional methods.
- Broad-Spectrum Neutralization: JMB2002 demonstrated potent activity against a wide range of SARS-CoV-2 variants, including those known to be resistant to other antibodies, highlighting its potential as a universal therapeutic.
- ADE Mitigation: The introduction of the N297A mutation successfully reduced ADE activity while preserving the antibody's potent neutralizing capacity, addressing a critical safety concern for antibody therapeutics.
- In Vivo Efficacy: The rhesus macaque model provided strong evidence for JMB2002's ability to confer complete prophylactic protection and significant therapeutic benefits, including reduced lung damage.
Key Results
- Identification of Potent Antibodies: The PtY platform successfully identified two potent nAbs, with JMB2002 emerging as the lead candidate.
- In Vitro Blocking Activity: JMB2002 showed broad-spectrum in vitro blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants, including B.1.351.
- Live Virus Neutralization: JMB2002 exhibited potent live virus-neutralizing activity, reducing viral load in a rhesus macaque model by over 3 logs compared to controls.
- Prophylactic and Therapeutic Efficacy: In rhesus macaques, a single dose of JMB2002 before infection provided complete prophylactic protection, and therapeutic administration significantly reduced viral load and lung damage.
- Good Manufacturability: JMB2002 demonstrated favorable CMC (Chemistry, Manufacturing, and Controls) development characteristics, including a high expression titer (6 g/L) and good thermal stability.
Limitations and Future Work
- ADE Risk: While the N297A mutation significantly reduced ADE, the authors acknowledge that ADE can be complex and further investigation into Fc-mediated effector functions and their balance with ADE risk is warranted.
- Combination Therapies: The paper suggests that optimizing the sequence of Ab2001.10 for potential therapeutic application in combination with JMB2002 could be considered, as they recognize different epitopes. Bispecific antibodies are also proposed as a more attractive approach due to shorter development times and lower manufacturing costs.
- Clinical Trials: JMB2002 is currently in Phase I clinical trials, and future work will focus on its efficacy and safety in human patients. The authors aim for JMB2002 to be approved for COVID-19 treatment, contributing to both treatment and the understanding of Fc modification impacts on viral infection therapies.
Summary updated